Background

Infectious diseases pose a serious threat to humankind and global economy [1]. Antimicrobial resistance (AMR), gave rise to the situation of global health emergency [2]. Once bacteria come in contact with an exposed wound, they consume nutrients from surrounding and initiate the formation of biofilm at an alarming rate, which is much faster in diabetic patients [3]. Conventional antibiotics such as streptomycin and vancomycin combat bacterial infections by causing irreparable damage to the bacteria through various mechanisms like inhibition of essential proteins [4]. Antibiotics not only treat microbial infections but also play an indispensable role in preventing severe infections in chronically ill patients such as diabetes and renal disease or who have had complex surgeries [5, 6]. Emergence of AMR along with massive reports of overdose or misuse of administered antibiotics are responsible for impotency of existing antibiotics [7]. From the year of 2050, microbial infections will account for the death of more than 10 million people per year [8]. Moreover, multidrug resistance (MDR) bacteria can produce enzymes to degrade or inactivate antibiotics, or to alter bacterial efflux pumps, targeting binding sites, and entry ports to inhibit antibiotics [9]. With the deteriorating efficiency of currently available antibiotics and growing AMR, it is of great importance to discover alternative strategies against infectious diseases.

To circumvent the challenges associated with AMR, various carbon-, metal/metal oxide-, and two-dimensional (2D) nanomaterial-based antimicrobial modalities have been developed to disintegrate bacteria via complex mechanisms, including disruption of bacterial membranes, proteolysis, degradation of DNA, or elevated oxidative stress [10,11,12,14,15,16]. These nanomaterials that are often recognized as “endogenous antimicrobial” can delay bacterial damage, and thus repeated administration inevitably leads to AMR [17]. In addition, cytotoxicity of metal ions leached out from nanoparticle surfaces is also a concern [18]. Although surface passivation is feasible using small organic ligands, polymers, and biomacromolecules, antibacterial activity is compromised [19]. Therefore, development of biocompatible nanomaterials that offer multiple routes of biocidal action in vivo systems or clinical settings is a colossal challenge.

Ultrathin 2D nanomaterials with the lateral size larger than 100 nm and thickness of only a single- or few-atoms thick (< 5 nm) represent an emerging class of antimicrobials, mainly due to their huge specific surface and faster electron transfer ensuring sufficient surface-active sites [20,21,22]. For example, Zhao et al. reported highly catalytic reduced graphene oxide nanosheets for antimicrobial therapies [23]. The nanosheets provided therapeutic potency against MDR bacteria; however, they were non-responsive to near-infrared (NIR) irradiation, and thus they do not allow in-depth tissue penetration and generation of localized heat (> 50 °C) to inactivate the bacteria. Another report, Ding et al. showed the synthesis of CuS/graphitic carbon nitride (g-C3N4) heterojunctions for NIR-laser irradiation-assisted photothermal therapy [24]. Although the heterojunctions induced faster electron transfer to promote photocatalytic performance, they could not generate H2O2.

Currently, MXene is a fast-growing family of 2D materials, comprised of transition metal carbides, carbonitride, and nitrides with a general formula of Mn+1XnTx, where M is an early transition metal (e.g., Sc, Ti, V, Cr, Zr, Nb, Mo, Hf), X is carbon and/or nitrogen, and Tx is a surface terminal group (–F, –OH, –O, etc.) [25,Full size image